CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study

A cross-sectional analysis

V. Fridman, B. Bundy, M. M. Reilly, D. Pareyson, C. Bacon, J. Burns, J. Day, S. Feely, R. S. Finkel, T. Grider, C. A. Kirk, D. N. Herrmann, M. Laurá, J. Li, T. Lloyd, C. J. Sumner, F. Muntoni, G. Piscosquito, S. Ramchandren, R. Shy & 7 others C. E. Siskind, S. W. Yum, I. Moroni, E. Pagliano, S. Zuchner, S. S. Scherer, M. E. Shy

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them. Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES). Results: 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported. Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT. Clinical trial registration ID number NCT01193075.

Original languageEnglish
Pages (from-to)873-878
Number of pages6
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume86
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Charcot-Marie-Tooth Disease
Natural History
Tooth
Cross-Sectional Studies
Mutation
Clinical Trials
Teeth
Burden
Longitudinal Studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)

Cite this

CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study : A cross-sectional analysis. / Fridman, V.; Bundy, B.; Reilly, M. M.; Pareyson, D.; Bacon, C.; Burns, J.; Day, J.; Feely, S.; Finkel, R. S.; Grider, T.; Kirk, C. A.; Herrmann, D. N.; Laurá, M.; Li, J.; Lloyd, T.; Sumner, C. J.; Muntoni, F.; Piscosquito, G.; Ramchandren, S.; Shy, R.; Siskind, C. E.; Yum, S. W.; Moroni, I.; Pagliano, E.; Zuchner, S.; Scherer, S. S.; Shy, M. E.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 86, No. 8, 01.08.2015, p. 873-878.

Research output: Contribution to journalArticle

Fridman, V, Bundy, B, Reilly, MM, Pareyson, D, Bacon, C, Burns, J, Day, J, Feely, S, Finkel, RS, Grider, T, Kirk, CA, Herrmann, DN, Laurá, M, Li, J, Lloyd, T, Sumner, CJ, Muntoni, F, Piscosquito, G, Ramchandren, S, Shy, R, Siskind, CE, Yum, SW, Moroni, I, Pagliano, E, Zuchner, S, Scherer, SS & Shy, ME 2015, 'CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: A cross-sectional analysis', Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 8, pp. 873-878. https://doi.org/10.1136/jnnp-2014-308826
Fridman, V. ; Bundy, B. ; Reilly, M. M. ; Pareyson, D. ; Bacon, C. ; Burns, J. ; Day, J. ; Feely, S. ; Finkel, R. S. ; Grider, T. ; Kirk, C. A. ; Herrmann, D. N. ; Laurá, M. ; Li, J. ; Lloyd, T. ; Sumner, C. J. ; Muntoni, F. ; Piscosquito, G. ; Ramchandren, S. ; Shy, R. ; Siskind, C. E. ; Yum, S. W. ; Moroni, I. ; Pagliano, E. ; Zuchner, S. ; Scherer, S. S. ; Shy, M. E. / CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study : A cross-sectional analysis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2015 ; Vol. 86, No. 8. pp. 873-878.
@article{5ee4c8d580bb4339986a5a27c5ce1a97,
title = "CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: A cross-sectional analysis",
abstract = "Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them. Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES). Results: 997 of the 1652 patients (60.4{\%}) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2{\%} of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported. Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT. Clinical trial registration ID number NCT01193075.",
author = "V. Fridman and B. Bundy and Reilly, {M. M.} and D. Pareyson and C. Bacon and J. Burns and J. Day and S. Feely and Finkel, {R. S.} and T. Grider and Kirk, {C. A.} and Herrmann, {D. N.} and M. Laur{\'a} and J. Li and T. Lloyd and Sumner, {C. J.} and F. Muntoni and G. Piscosquito and S. Ramchandren and R. Shy and Siskind, {C. E.} and Yum, {S. W.} and I. Moroni and E. Pagliano and S. Zuchner and Scherer, {S. S.} and Shy, {M. E.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1136/jnnp-2014-308826",
language = "English",
volume = "86",
pages = "873--878",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study

T2 - A cross-sectional analysis

AU - Fridman, V.

AU - Bundy, B.

AU - Reilly, M. M.

AU - Pareyson, D.

AU - Bacon, C.

AU - Burns, J.

AU - Day, J.

AU - Feely, S.

AU - Finkel, R. S.

AU - Grider, T.

AU - Kirk, C. A.

AU - Herrmann, D. N.

AU - Laurá, M.

AU - Li, J.

AU - Lloyd, T.

AU - Sumner, C. J.

AU - Muntoni, F.

AU - Piscosquito, G.

AU - Ramchandren, S.

AU - Shy, R.

AU - Siskind, C. E.

AU - Yum, S. W.

AU - Moroni, I.

AU - Pagliano, E.

AU - Zuchner, S.

AU - Scherer, S. S.

AU - Shy, M. E.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them. Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES). Results: 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported. Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT. Clinical trial registration ID number NCT01193075.

AB - Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them. Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES). Results: 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported. Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT. Clinical trial registration ID number NCT01193075.

UR - http://www.scopus.com/inward/record.url?scp=84940645158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940645158&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2014-308826

DO - 10.1136/jnnp-2014-308826

M3 - Article

VL - 86

SP - 873

EP - 878

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 8

ER -